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Abstract
BACKGROUND: Of all cancer tumours, urinary bladder cancer
is the fourth must common in men and the seventh in women.
The aim of this work was to answer the question whether tissue
polypeptide antigen (TPA-M) determination in patients after elec-
troresection of urinary bladder cancer can be used to establish
the probability of tumour recurrence.
MATERIAL AND METHODS: The research included 98 patients,
all of whom had undertaken electroresection of urinary bladder
tumour (TURT), which enabled its removal, and then estima-
tion of malignancy and progression stage according to the in-
ternational TNM scale. The mean age was 62.7 years. All pa-
tients had blood samples taken to determine TPA-M and then
underwent routine cystoscopy examination.
RESULTS: The patients with tumour recurrence (60, mean age
64 ± 10) had TPA 30.2 ± 4.3 U/l, the patients without recur-
rence (38, mean age 61.3 ± 11) had TPA-M 26.2 ± 3.18 U/l
(p > 0.1). Taking the TPA-M threshold point 85 U/l as normal,
true-positive results were 16.3%, true-negative were 31.6%, false-
positive results were 7.1% and false-negative were 44.9%. The
ROC curves with the calculated area under them are the mea-
surement of the diagnostic estimation of TPA-M concentrations
in specificity and sensitivity categories.
CONCLUSIONS: For the examined group the calculated P
was 0.45. If P value is under 0.5 it is considered that the test
should not be used in diagnosing recurrence of urinary blad-
der cancer.
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Introduction
Urinary bladder cancer is one of the most often occurring
malicious tumours. Initially urinary bladder cancer develops in-
traepithelium, however most first detected cancers take the form
of superficial papilloma, which if not treated infiltrates into the sub-
mucosa and muscular layer as well as into neighbouring organs.
Transurethral resection of tumour (TURT) is a basic method of
treatment of superficial urinary bladder cancer. For patients with
tumour resection, the cystoscopic check-ups were performed three
months after operation in order to establish a probability of tu-
mour recurrence. Staging and grading of the tumour were esti-
mated after TURT by histopathological examination.  To diagnose
the possibility of recurence, for patients with tumour resection
cystoscopic check-up was performed after three months. After
resection continual cystoscopic check-ups are necessary. The aim
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groups were assessed using the Kolmogorov-Smirnov two-sam-
ple test. P values of < 0.05 were considered statistically signifi-
cant. ROC curve is presented of the TPA depicting the true-posi-
tive rate (sensitivity) v. the false-positive rate. The area under the
curve was calculated with the Wilcoxon statistic [6–8].
Results and discussion
All patients were divided into two subgroups depending on
the result of check-up cystoscopy: the patients with recurrence
(60 people, mean age 64 ± 10) and patients without recurrence
(38 people, mean age 61.3 ± 11). The percentage of patients
according to the progression stage of urinary bladder cancer in
both subgroups is presented in Figure 1. Mean geometrical con-
centration of TPA-M in the group of patients with recurrence of
cancer was 30.2 ± 4.3 U/l and in the group of patients without
recurrence of cancer it was 26.2 ± 3.18 U/l, the difference not
being statistically significant. Mean geometrical concentration of
TPA-M together with geometrical standard deviation according to
the progression stage of urinary bladder cancer in both subgroups
are presented in Table 1.
Taking the physiological norm for TPA-M as 85 U/l, true-pos-
itive results make up 16.3%, true-negative 31.6%, false-positive
7.1% and false-negative 44.9%. The measurement of the com-
plete assessment of the diagnostic precission of TPA-M concen-
tration in monitoring the effectiveness of treatment using the TURT
method in categories of specificity and sensitivity is the evaluation
of ROC curve and calculation of the area under the curve (Fig. 2).
For the studied group of patients this value was P = 0.45.
Analysing the percentage of patients in subgroups differing in
the progression stage of urinary bladder cancer, it can be said
is to exclude any recurrence or progression appearing as an in-
crease of tumour local progression. No reliable tumour markers
are available for urinary bladder cancer [1].
Bjorklund discovered tissue polypeptide antigen (TPA) in can-
cer tissue. This is a complex of polypeptide fragments of cytoker-
atin 8, 18 and 19 circulating in blood, appearing commonly in
healthy epithelium as well as in epithelium-derived tumours. TPA
is a single protein of 43 kDt molecular mass. This is protein of
cellular and cytoplasmic membrane synthetised mainly in stage S
of cellular divisions. It has two specific epitopes of cytokeratin 18
which are also found in tissue polypeptide special antigen (TPS),
that is why TPA was considered to be a proliferation marker (its
second name is prolifigen), but now it is known as an apoptosis
marker.
It possesses also 33 nonspecified epitopes, some with
epitopes of cytokeratin 8, 18 and 19. In urinary bladder tumour
cells TPA exists mostly on the tumour surface in proliferation plac-
es — group of cells attacking surrounding tissue [2, 3]. Serum
TPA is a clinically appreciated marker of monitoring patients with
tumours originating from epithelial cells, e.g. neoplasma of lungs
[4], breast [5], large intestine and urinary bladder. Its physiologi-
cal concentration in serum should not exceed 85 U/l.
The aim of this research was to find out whether monitoring
TPA-M in patients after electroresection of urinary bladder cancer
is useful in the detection of the probability of tumour recurrence.
Material and methods
98 patients were taken under research, all of whom underwent
electroresection of urinary bladder cancer (mean age 62.7 years).
During the three-month period no cytostatic drugs were adminis-
tered. In the case of tumour recurrence the second check-up al-
lowed the next histopatological examination to be performed. TPA
was estimated during routine check-ups three months after the
operation (TURT). Blood samples were taken before cystoscopy.
The progression stage and malignancy of the tumour TURT was
estimated in the case of recurrence after the next TURT. Serum
TPA was determined using the Prolifigen TPA-M IRMA kit sup-
plied by Byk-Sangtec. In this kit monoclonal antibodies against
TPA are used for immunological reaction. Radioactivity of obtained
complexes was measured in two-detector gamma Wallac-Wiz-
ard-1470 radiation meter.
Statistical analysis
The values obtained are expressed as a geometric mean and
a geometric standard deviation. Differences between distribution
Table 1. Concentration of TPA according to the progression stage of urinary bladder cancer
Geometric means with geometric standard deviation TPA [U/l]
Stage infiltration T1 T1–2 T2  T3 T4
With recurrence
(n = 60) 30.4 ± 3.12 10.2 ± 6.65 23.2 ± 4.44 44.36 ± 4.15 161.6 ± 1.71
Without recurrence
(n = 38) 25.5 ± 3.25 32.5 ± 2.03 24.7 ± 3.77 32.32 ± 1.76
Stage of infiltration of the urinary bladder: T1 — epithelium, T2 — stroma interstitium, T3 — muscular layer, T4 — perivesical fatty tissue,
infiltration stages T1–T4 with recurrence has been obtained after the second electroresection, whereas T1–T4 without recurrence are after the
first electroresection
Figure 1. The percentage of patients according to the progression stage
of urinary bladder cancer.
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that most patients, both cured and with recurrence, were with the
cancer infiltrating the stroma (T2). They are also the largest num-
ber of patients of the urology department treated with electrore-
section because of urinary bladder cancer.
Analysing mean geometrical values of TPA-M concentrations
in subgroups of patients both with and without recurrence no func-
tional dependence was found between obtained concentrations
of TPA-M and progression stages of urinary bladder cancer. In
patients both with and without recurrence in whom cancer in T1,
T1/2, T2 stage was diagnosed, mean geometrical TPA-M con-
centrations oscillated between 10 and 30 U/l. The lack of a clear
difference in TPA-M concentrations between patients both with
and without recurrence confirms the lack of a statistically signifi-
cant difference between patients with and without recurrence. The
highest mean geometrical TPA-M concentrations twice exceed-
ing the physiological norm were found in patients with recurrence
in whom urinary bladder cancer of T3/4 stage was diagnosed.
Similar results can be found in literature [1, 9–11]. Estimating di-
agnostic usefulness of TPA-M estimation in monitoring the effec-
tiveness of treatment of urinary bladder cancer using the TURT
method in the category of the number of true-positive or false-
negative results, taking threshold point as 85 U/l, it was shown
that the percentage of true-positive results was low (16.3%) and
of false-negative results was high (44.9%). The question is wheth-
er for patients monitored for the effectiveness of treatment of uri-
nary bladder cancer a different threshold point for TPA-M test than
for TPA test should be taken. The results published by Bennink
show that TPA-M test is more precise and has clinical use in the
follow-up of bladder cancer patients with poorly differentiated su-
perficial, locally advanced tumour or systemic disease after cura-
tive or palliative therapy [12]. The study of the ROC curve and
calculation of the value of the area under the curve below 0.5 shows
unambiguously that the value of serum TPA-M concentration esti-
mated three months after TURP cannot be the basis of the prog-
nosis of the progression stage in cases of low progression stage
tumours [13].
Conclusions
Estimation of TPA-M at check-ups in patients after urinary blad-
der cancer electroresection is useless for establishing the proba-
bility of tumour recurrence.
High TPA concentration was however found in patients with
advanced stage of the disease (T3–4).
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Figure 2. The receiver-operating characteristic (ROC) curve for retro-
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